doi: 10.1007/978-1-4684-5826-8_11 15 FrioletRHoppelerHKrahenbuhlS
Goldman, MD, is the founder and medical director of Cosmetic Laser Dermatology and a board-certified dermatologist recognized internationally for his expertise in cosmetic dermatology, laser treatments, vein care, and injectables
Clinical therapeutic effects and challenges of GLP-1 receptor agonists The primary GLP-1RAs used worldwide as anti-obesity drugs are liraglutide (Saxenda, Novo Nordisk) as a once-daily subcutaneous injection and semaglutide (Wegovy, Novo Nordisk) as a once-weekly subcutaneous injection
Most patients will see better results at higher doses, but also may experience worse side effects
Many people choose steady sips throughout the day and pause fluids around mealtimes to keep meals more comfortable
Side effect profiles are broadly similar between the two medications